The FINANCIAL -- Royal Philips has acquired the CE mark for diagnostic use of its Philips Digital Pathology Solution. European pathologists will now be able to use the full digital solution as an aid in diagnosis for routine pathology, such as primary diagnosis of oncology, according to Koninklijke Philips N.V.
With the aging population and the increasing knowledge of the complexity of cancer cases, improving the efficiency and quality of cancer diagnostics has become a critical concern. By digitizing the images pathologists normally view through a microscope, Philips’ solution offers high-quality images that could enable a more objective and quantitative diagnosis than currently possible. These digital images could also enable new ways to mine information from tumor tissue for further data analysis. Additionally, enhanced collaboration capabilities may speed up consults and second opinions which could improve diagnostic confidence.
“Pathologists play a critical role in the increasing demand for cancer diagnosis and care, and digital pathology looks promising in its ability to support faster, more confident diagnosis,” said Perry van Rijsingen, General Manager of Philips Digital Pathology Solutions. “Helping improve workflows and collaboration could increase efficiency and productivity, and we believe that digitization will arm pathologists with the resources they need to successfully improve diagnostics.”
The CE mark includes diagnosis for routine pathology including Hematoxylin and Eosin (H&E), Immunohistochemistry (IHC) and special stained tissue sections.
Through the Digital Pathology Solution, Philips strives to enable a faster and simplified pathology workflow and improved outcomes to make pathology labs more efficient. The digitization of pathology workflow is expected to ease logistical burdens and enables new ways of working, such as real-time collaboration between pathologists, the creation of virtual networks and the use of dedicated software tools, according to Koninklijke Philips N.V.